Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy

The myeloid tumor suppressor KMT2C is recurrently deleted in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly therapy-related MDS/AML (t-MDS/t-AML), as part of larger chromosome 7 deletions. Here, we show that KMT2C deletions convey a selective advantage to hematopoietic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Rep
Hauptverfasser: Chen, Ran, Okeyo-Owuor, Theresa, Patel, Riddhi M., Casey, Emily B., Cluster, Andrew S., Yang, Wei, Magee, Jeffrey A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951951/
https://ncbi.nlm.nih.gov/pubmed/33596429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2021.108751
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge